Bioventix (LON:BVXP) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Bioventix PLC (LON:BVXP) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,763.27 and traded as low as GBX 1,600. Bioventix shares last traded at GBX 1,665, with a volume of 12,235 shares changing hands.

Bioventix Stock Up 0.9%

The company’s fifty day moving average is GBX 1,632.97 and its two-hundred day moving average is GBX 1,763.27. The firm has a market capitalization of £87.00 million, a price-to-earnings ratio of 11.85 and a beta of 0.56.

Bioventix (LON:BVXP) last announced its quarterly earnings data on Monday, March 30th. The biotechnology company reported GBX 69.38 earnings per share for the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%. The business had revenue of GBX 615.88 billion for the quarter. On average, equities research analysts expect that Bioventix PLC will post 166.3066955 EPS for the current year.

Insider Activity at Bioventix

In other Bioventix news, insider Peter John Harrison acquired 1,065 shares of the business’s stock in a transaction that occurred on Wednesday, April 8th. The shares were acquired at an average cost of GBX 1,849 per share, for a total transaction of £19,691.85. Also, insider Bruce Hiscock acquired 66 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average price of GBX 1,679 per share, for a total transaction of £1,108.14. Insiders have acquired 2,131 shares of company stock worth $3,927,999 over the last ninety days. Company insiders own 6.16% of the company’s stock.

Bioventix Company Profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.